Dexamethasone plus rituximab yields higher

Dexamethasone plus rituximab yields higher sustained
response rates than dexamethasone monotherapy in
adults with primary immune thrombocytopenia
by Francesco Zaja, Michele Baccarani, Patrizio Mazza, Monica Bocchia, Luigi
Gugliotta, Alfonso Zaccaria, Nicola Vianelli, Marzia Defina, Alessia Tieghi, Sergio
Amadori, Selenia Campagna, Felicetto Ferrara, Emanuele Angelucci, Emilio Usala,
Silvia Cantoni, Giuseppe Visani, Antonella Fornaro, Rita Rizzi, Valerio De Stefano,
Francesco Casulli, Marta Lisa Battista, Miriam Isola, Franca Soldano, Enrica Gamba,
and Renato Fanin
Blood
Volume 115(14):2755-2762
April 8, 2010
©2010 by American Society of Hematology
Consolidated Standards of Reporting Trials (CONSORT) flow diagram of progress through the
study phases.
Francesco Zaja et al. Blood 2010;115:2755-2762
©2010 by American Society of Hematology
Kaplan-Meier response duration curves after month 6 in patients who achieved sustained
response (SR) after dexamethasone monotherapy, dexamethasone plus rituximab, and
dexamethasone plus rituximab salvage therapy.
Francesco Zaja et al. Blood 2010;115:2755-2762
©2010 by American Society of Hematology